AcuCort AB (ACUC.ST), a Swedish biotechnology company, on Thursday said it has signed a commercial agreement with Glenmark Pharmaceuticals Ltd. (GLENMARK.NS) for the marketing and distribution of Zeqmelit in six European countries, including Germany.
The financial terms were not disclosed.
The agreement marks a key step in AcuCort's international expansion strategy.
Under the agreement, which replaces a previously announced letter of intent, Glenmark will be responsible for commercialisation in Germany, the Netherlands, the Czech Republic, Austria, Slovakia and Ukraine, covering a combined population of more than 160 million.
The marketing authorisation applications are expected to be filed in the second half of 2026.
Glenmark Pharmaceuticals is currently trading 1.96% higher at INR 1,979.20 on the National Stock Exchange.
On Wednesday, AcuCort AB closed trading 0.16% higher at SEK 0.6110 on the Stockholm Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.